Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- GLP-1 weight-loss clinical trials are regulated studies that generate the safety and efficacy data used for FDA approvals and obesity treatment guidelines.
- Retatrutide currently leads late-stage efficacy with up to 28%+ weight reduction in Phase 3 trials, while oral agents like aleniglipron reach 16.3% placebo-adjusted loss.1
- Most recruiting trials require BMI ≥30 or BMI ≥27 with comorbidities, with strict exclusion criteria such as prior bariatric surgery and specific medical conditions.
- Muscle preservation is a growing research focus, and trials like BELIEVE show that bimagrumab plus semaglutide can shift weight loss almost entirely to fat mass.
- Individuals who do not qualify for trials or prefer supervised alternatives can book a consultation at Mirror Plastic Surgery for lab-guided GLP-3R peptide protocols.
GLP-1 and Oral Agent Efficacy Overview
The table below summarizes key recruiting or recently completed late-stage trials and highlights the current efficacy spread. Injectable triple agonists sit at the top of the range, while oral agents are closing the gap as programs mature. Weight-loss figures reflect the primary efficacy estimand unless otherwise noted, and all NCT IDs link directly to ClinicalTrials.gov or sponsor pages.
Record-Setting Weight Loss in GLP-1 Trials
Retatrutide produced 28.7% mean body weight reduction at 68 weeks in the Phase 3 TRIUMPH-4 trial, the highest figure reported in any late-stage obesity trial to date.1 The highest-dose arm exceeded 30% weight reduction in the extension phase out to 104 weeks, approaching outcomes historically seen with bariatric surgery.1
How Oral GLP-1 Agents Stack Up in 2026
Oral aleniglipron achieved up to 16.3% placebo-adjusted weight loss at 44 weeks, which currently represents the highest reported weight loss for any oral GLP-1 receptor agonist.1 Elecoglipron reached 11.8% at 36 weeks in the obesity cohort, while orforglipron 36 mg produced 9.2% weight loss at 52 weeks in adults with type 2 diabetes inadequately controlled on metformin.1 Injectable triple agonists such as retatrutide still lead on absolute efficacy, but the gap is narrowing.
Active Recruiting GLP-1 and Related Studies
Retatrutide Weight Loss Trial (TRIUMPH Program)
Eli Lilly plans to submit a Biologics License Application for retatrutide to the FDA in Q1 2027 following five positive Phase 3 studies. The ongoing TRIUMPH-5 trial is conducting a head-to-head comparison with tirzepatide.
ACCOMPLISH-1 — Aleniglipron Phase 3 (NCT07654361)
NCT07654361 (ACCOMPLISH-1) is a Phase 3 multicenter, global, randomized, placebo-controlled trial sponsored by Gasherbrum Bio evaluating once-daily oral aleniglipron for chronic weight management, with an estimated study start date of July 2026.
Eligibility criteria for NCT07654361 include:
- BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one obesity-related comorbidity
- Adult age (18 years or older)
- Willingness to follow a reduced-calorie diet and increased physical activity for at least 76 weeks
- No disqualifying hepatic or cardiac conditions, with no drug-induced liver injury or QTc prolongation observed in prior aleniglipron studies
Enicepatide Phase 3 Trials (NCT07351058 / NCT07351045)
Genentech is conducting two recruiting Phase 3 trials of enicepatide (RO7795068), a once-weekly subcutaneous biased dual GLP-1/GIP receptor agonist. One trial enrolls adults with obesity or overweight and type 2 diabetes, and the other focuses on adults with obesity or overweight without type 2 diabetes.
Pfizer SOLIS-1 (NCT07575932)
Pfizer’s SOLIS-1 trial evaluates a GLP-1 receptor agonist and an amylin analog alone and in combination for weight management in adults with overweight or obesity. Eligibility requires age 18 or older, BMI 30–50 or BMI 27–29 with a weight-related comorbidity, and no type 2 diabetes diagnosis. All study visits and investigational medicines are provided at no cost to participants.
AMAZE 1 — NNC0487-0111 (NCT07339423)
The AMAZE 1 Phase 3 trial sponsored by Novo Nordisk is investigating once-weekly subcutaneous NNC0487-0111 versus placebo for obesity in 1,150 adults aged 18 and older. The trial runs from February 2026 through August 2029 across sites including the United States.
Typical Eligibility for GLP-1 Clinical Trials
Most 2026 recruiting trials share a common eligibility framework. Participants generally need BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one comorbidity such as hypertension, dyslipidemia, or sleep apnea. Many trials exclude individuals with active type 2 diabetes, prior bariatric surgery, or serious hepatic or cardiovascular conditions. Specific NCT-level criteria always supersede general guidance.
How to Join a GLP-1 Trial
The steps below outline how most U.S.-based GLP-1 obesity trials work, including Florida sites.
- Confirm baseline eligibility. Confirm baseline eligibility by calculating your BMI and documenting any comorbidities such as hypertension, dyslipidemia, or sleep apnea. These two data points determine whether you meet the common threshold of BMI ≥27 with at least one comorbidity, or BMI ≥30 without.
- Gather recent lab work. Collect results for HbA1c, fasting glucose, lipid panel, comprehensive metabolic panel for kidney and liver function, and TSH. These markers align with the baseline and periodic monitoring recommended for GLP-1 therapies.
- Search ClinicalTrials.gov. Use search terms such as “GLP-1 obesity” or “GLP-1 weight loss” and filter by “Recruiting” status and your state, for example Florida. Review the NCT IDs listed above as starting points.
- Contact the study coordinator. For ACCOMPLISH-1, the study contact is the Medical Director at Gasherbrum Bio at [email protected] or 1-650-457-1959.
- Complete pre-screening. Most trials require a phone or video pre-screen before an in-person visit. Disclose all current medications, prior GLP-1 use, and surgical history.
- Attend the in-person screening visit. Expect a physical examination, ECG, and repeat lab draws. You will review and sign informed consent at this visit.
- Await randomization. If you qualify, the site randomizes you to active drug or placebo. Trials such as SOLIS-1 include approximately 24 clinic visits over 18 months.
Common Reasons for GLP-1 Trial Disqualification
Common exclusion criteria across 2026 trials include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, active pancreatitis, severe renal impairment, prior bariatric surgery, and current use of other investigational weight-loss agents. Permanent discontinuation rates in trials such as SELECT reached 16.6% in the active arm, driven overwhelmingly by gastrointestinal adverse events, and coordinators consider this risk when screening.
Many individuals who do not qualify for a trial, or who prefer a supervised, lower-side-effect alternative, are strong candidates for Mirror Plastic Surgery’s concierge GLP-3R protocol. Schedule a lab review with Ellie to determine whether a medically supervised peptide protocol fits your eligibility and goals.
Oral, Injectable, and Triple-Agonist Updates
Before committing to a trial, it helps to understand how the agent you may receive compares with the broader pipeline. The 2026 landscape spans three main categories, and each has different efficacy and tolerability profiles that can shape your decision.
Oral agents such as aleniglipron, elecoglipron, and orforglipron remove the need for subcutaneous injections and still provide meaningful weight loss. Orforglipron 36 mg produced 9.2% weight loss at 52 weeks in adults with type 2 diabetes inadequately controlled on metformin. However, treatment discontinuation due to adverse events occurred in 9.7% of participants on orforglipron 36 mg versus 4.9% on oral semaglutide 14 mg, with nausea, diarrhea, and vomiting most common.
Dual agonists such as survodutide, a GLP-1 and glucagon agonist, add glucagon receptor activation to increase fat oxidation. Boehringer Ingelheim is also advancing an investigational triple GLP-1/GIP/NPY2 receptor agonist peptide, BI 3034701, which enters Phase 2 in mid-2026.
Triple agonists such as retatrutide activate GIP, GLP-1, and glucagon receptors at the same time. Cross-trial comparisons indicate retatrutide produced greater weight loss, up to about 30%, than tirzepatide at roughly 20% or semaglutide at roughly 14%.1 although no head-to-head trial with semaglutide has finished.
Side Effect Profiles: Retatrutide, Orforglipron, and GLP-3R
Roughly 18% of participants on the highest retatrutide dose discontinued treatment because of side effects. Orforglipron’s most common adverse events were nausea, diarrhea, vomiting, dyspepsia, and decreased appetite. Mirror Plastic Surgery’s GLP-3R compounding protocol is reported to carry fewer gastrointestinal symptoms than older GLP-1 formulations, with a lower likelihood of muscle wasting and broader metabolic indications including insulin resistance and cardiovascular risk factors. Individual responses still vary, so lab-guided dosing remains essential.
Muscle-Preservation Strategies in GLP-1 Therapy
GLP-1 receptor agonist therapies such as semaglutide are associated with 25%–40% of total weight loss deriving from skeletal muscle or other fat-free mass rather than adipose tissue. This pattern has driven a parallel research effort to identify co-interventions that preserve lean mass during GLP-1-mediated weight loss.
Bimagrumab plus semaglutide (BELIEVE trial). The BELIEVE Phase 2 randomized clinical trial, published in Nature Medicine in March 2026, found that combining semaglutide with bimagrumab, an activin-signaling blocker, produced 22.1% average body weight loss over 72 weeks.1 In this study, 92.8% of weight lost consisted of fat mass, and lean mass remained largely preserved.1 Bimagrumab alone produced 10.8% average weight loss.1
Resistance exercise plus protein supplementation (NCT06885736). A 2026 randomized controlled trial at Dasman Diabetes Institute is enrolling 232 adults with obesity. The trial tests whether resistance exercise three times weekly and protein intake targeting 1.6 g/kg/day can preserve muscle mass during semaglutide or tirzepatide therapy, using MRI-measured quadriceps cross-sectional area as the primary outcome.
Enobosarm plus GLP-1 (QUALITY trial, NCT06282458). The ongoing QUALITY trial is evaluating enobosarm in patients taking a GLP-1 medication for chronic weight management, representing a selective androgen receptor modulator strategy for lean mass preservation.
Role of GHRPs Like Sermorelin or Ipamorelin
Preclinical data show that co-administration of GLP-1R agonists with anti-ActRII antibodies or antibodies blocking myostatin and Activin A preserved or increased skeletal muscle mass while markedly enhancing fat loss in obese mice and non-human primates. Growth hormone releasing peptides such as sermorelin and ipamorelin stimulate natural growth hormone production through a related but distinct pathway. No large randomized controlled trial has yet tested GHRPs specifically as a muscle-preservation co-intervention during GLP-1 therapy, yet their anabolic mechanism makes them a logical component of a supervised peptide protocol. Ellie considers this option case by case after reviewing lab results.
Supervised Peptide Alternatives for Muscle-Aware Weight Loss
The muscle-preservation strategies described above remain in clinical trials and are not yet standard care. For individuals who want muscle-aware weight management now, or who do not meet trial eligibility criteria, Mirror Plastic Surgery offers a GLP-3R compounding protocol led by Ellie Pranckevicius, FNP-BC.
GLP-3R is a newer-generation peptide similar in mechanism to GLP-1 but reported to carry fewer gastrointestinal symptoms, a lower likelihood of muscle wasting, and broader metabolic indications including insulin resistance, weight management, and cardiovascular risk factors. The protocol at Mirror Plastic Surgery includes:
- A comprehensive 30–60 minute consultation with Ellie that reviews full medical history and health goals
- In-depth lab panel review covering thyroid, liver, kidney, diabetes markers, and hormone panels, ordered when not already available
- Custom peptide stack design based on individual lab results, which may pair GLP-3R with GHRPs such as sermorelin or ipamorelin for muscle preservation, or BPC-157 for systemic inflammation management
- Peptides sourced from reputable providers with rigorous batch testing for purity and accurate dosage
- Direct 24/7 concierge access to Ellie via text for ongoing support, dosing questions, and refill requests
- Remote service delivery available across the United States, including Hawaii and Alaska
Clinical trial data for approved GLP-1 therapies indicate that patients regain most or all lost weight after stopping treatment, which suggests that long-term administration or ongoing supervised protocols may be necessary for sustained results. Mirror Plastic Surgery’s concierge model is built for this kind of long-term, personalized management.
Start your consultation with Ellie to receive a lab-guided assessment and a peptide protocol tailored to your metabolic profile and weight-loss goals.
Frequently Asked Questions
Are GLP-1 clinical trials free to participate in?
Many GLP-1 clinical trials cover all study-related visits, assessments, counseling, and investigational medicines at no cost to participants, and some reimburse transportation and parking. Not every trial offers compensation, and eligibility screening still requires time and travel. Individuals who do not qualify or prefer not to wait for enrollment can consider medically supervised peptide alternatives such as Mirror Plastic Surgery’s GLP-3R protocol, which operates as a private concierge service with lab-guided dosing from the start.
What happens to weight loss if I stop GLP-1 therapy?
Weight regain after stopping GLP-1 therapy appears consistently across multiple long-term studies. Appetite-regulatory and metabolic pathways that GLP-1 agents modulate tend to return toward baseline once the drug clears, and many patients regain a substantial portion of lost weight without continued treatment. Mirror Plastic Surgery therefore emphasizes ongoing maintenance protocols rather than brief courses, and Ellie works with each patient to build a long-term plan that reflects their physiology, lifestyle, and lab markers.
Is GLP-3R FDA-approved?
GLP-3R compounding, like many peptide therapies, is not FDA-regulated in the same way as approved pharmaceuticals such as semaglutide or tirzepatide. The main risk with peptide therapies comes from obtaining them from unregulated sources without medical supervision, rather than from the peptides alone. Mirror Plastic Surgery sources GLP-3R from reputable compounding providers with rigorous batch testing for purity and accurate dosage, and Ellie provides full medical oversight including lab panels, dosing guidance, and ongoing monitoring throughout the protocol.
How does muscle loss during GLP-1 therapy affect long-term health?
Skeletal muscle is metabolically active tissue that supports insulin sensitivity, physical function, and resting energy expenditure. When a significant share of total weight loss during GLP-1 therapy comes from fat-free mass instead of adipose tissue, long-term consequences can include reduced strength, higher sarcopenia risk in older adults, and a lower resting metabolic rate that makes weight maintenance harder. Mirror Plastic Surgery addresses this by pairing GLP-3R protocols with GHRPs such as sermorelin and ipamorelin when lab results and patient goals support that approach, creating a stack designed to promote fat loss while supporting lean mass retention.
Who is a good candidate for Mirror Plastic Surgery’s GLP-3R protocol instead of a clinical trial?
Good candidates include individuals who do not meet BMI or comorbidity thresholds for current recruiting trials, who have been excluded because of prior GLP-1 use or other medical history, or who experience significant gastrointestinal side effects on approved agents. The protocol also suits people who prefer a personalized concierge approach with direct practitioner access and those who want muscle-preservation strategies integrated from the beginning. A consultation with Ellie, including lab review, is the first step in deciding whether this approach fits your profile.
Summary
The 2026 GLP-1 trial landscape spans oral and injectable agents achieving roughly 10%–28%+ weight reduction, with triple-agonist retatrutide leading on efficacy and oral formulations steadily narrowing the gap. Muscle preservation remains an active research priority, and the BELIEVE trial shows that bimagrumab plus semaglutide can shift weight loss almost entirely to fat mass. Trial eligibility is strict, gastrointestinal side effects drive meaningful discontinuation rates, and long-term safety data beyond three to five years are still developing. For patients who do not qualify or who prefer supervised alternatives, Mirror Plastic Surgery’s concierge GLP-3R protocol offers lab-guided, muscle-aware weight management with direct access to Ellie Pranckevicius, FNP-BC.
Meet with Ellie at Mirror Plastic Surgery in St. Petersburg, Florida, or remotely anywhere in the United States, to begin a 30–60 minute consultation that includes lab review and a personalized peptide protocol designed around your goals.
Medical and Regulatory Disclaimer: This article is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. GLP-3R compounding and other peptide therapies discussed herein are
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
